JAZZ Q3 2022 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$941M+12.2% YoY

Gross Profit

$807M85.8% margin

Operating Income

$25M2.6% margin

Net Income

-$20M-2.1% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+0.8%

Cash Flow

Operating Cash Flow

$418M

Free Cash Flow

$423M

Stock-Based Comp.

$57M

Balance Sheet

Total Assets

$10.4B

Total Liabilities

$7.6B

Stockholders' Equity

$2.7B

Cash & Equivalents

$839M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$941M	$838M	+12.2%
Gross Profit	$807M	$693M	+16.5%
Operating Income	$25M	$28M	-12.7%
Net Income	-$20M	-$53M	+62.8%

Revenue Segments

Xyrem

$256M27%

Xywav

$256M27%

Epidiolex/Epidyolex

$196M21%

Rylaze/Enrylaze

$74M8%

Zepzelca

$70M8%

Defitelio/Defibrotide

$49M5%

Vyxeos

$30M3%

Sativex

$3M0%

Other Products

$1M0%

Geographic Segments

UNITED STATES

$868M92%

Europe

$60M6%

Other Countries

$13M1%